Showing results (101-110 of 682) with videos related to
Sort By:
Pageof 69
Cancer|February 11, 2004
Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesAmit Panwalkar, Srdan Verstovsek, Francis J GilesCurrent Hematologic Malignancy Reports|August 3, 2019
Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK InhibitorsMinas P Economides, Srdan Verstovsek, Naveen PemmarajuJournal of Immunotherapy and Precision Oncology|June 6, 2022
Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor MonotherapySophia S Lee, Srdan Verstovsek, Naveen PemmarajuClinical Lymphoma, Myeloma & Leukemia|March 23, 2020
The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic ImplicationBridget K Marcellino, Srdan Verstovsek, John MascarenhasClinical Lymphoma & Myeloma|September 26, 2009
JAK2 inhibitors: A reality? A hope?Effrosyni Apostolidou, Hagop M Kantarjian, Srdan VerstovsekClinical Lymphoma, Myeloma & Leukemia|August 23, 2015
New Therapeutic Approaches in Polycythemia VeraLorenzo Falchi, Kate J Newberry, Srdan VerstovsekClinical Lymphoma, Myeloma & Leukemia|February 16, 2023
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for MyelofibrosisHelen T Chifotides, Lucia Masarova, Srdan VerstovsekHematology/Oncology Clinics of North America|March 1, 2021
Immunotherapy and Immunomodulation in Myeloproliferative NeoplasmsNaveen Pemmaraju, Natalie C Chen, Srdan VerstovsekBlood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Ruxolitinib: a targeted treatment option for patients with polycythemia veraKris Vaddi, Srdan Verstovsek, Jean-Jacques KiladjianCancer|June 22, 2011
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosisAlfonso Quintás-Cardama, Nitin Jain, Srdan VerstovsekPageof 69